Neogene Therapeutics is a biotech company providing cancer patients with T cell therapies targeting mutated proteins called neo-antigens.
Neogene Therapeutics provides cancer patients with T cell therapies targeting mutated proteins called neo-antigens. The company is developing novel technologies to enable the engineering of ‘designer T cells’ with neo-antigen specificities that display an optimized ability to seek and destroy cancer cells.
Neogene's platform allows for the isolation of neo-antigen specific TCR genes from tumor biopsies that are routinely obtained from cancer patients during treatment. The tumor-infiltrating lymphocytes (TIL) obtained by these tumor biopsies frequently express TCRs specific for mutated proteins found in cancer cells (neo-antigens). The company’s proprietary technology uses state-of-the-art DNA sequencing, DNA synthesis and genetic screening tools to identify such neo-antigen specific T cell receptor genes within tumor biopsies with high sensitivity, specificity and at scale.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 14, 2020 | Series A | $110M | 8 |
EcoR1 Capital
Jeito Capital Syncona Partners LLP |
— | Detail |
May 23, 2019 | Series Unknown | $15M | — | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
EcoR1 Capital | Yes | Series A |
Jeito Capital | Yes | Series A |
Syncona Partners LLP | Yes | Series A |
Polaris Partners | — | Series A |
Pontifax | — | Series A |
TPG | — | Series A |
Two River | — | Series A |
Vida Ventures | — | Series A |